Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholest
November 11, 2015 10:45 AM ESTUp to 53 percent Maximal and 47 percent Least Squares Mean Reduction in LDL-C Achieved at 6 Months after Single, Low-Volume, Subcutaneous Injection
ALN-PCSsc Also Achieves Major Reductions in Other Atherogenic Lipids, Including Lowering of Lp(a) and Total Cholesterol of up to 77 percent and 55 percent, Respectively
Companies On Track to Initiate ORION-1 Phase 2 Trial by End-2015
Companies to Host Conference Call Today at 4:30 p.m.
CAMBRIDGE, Mass. & PARSIPPANY, N.J.--(BUSINESS WIRE)--... More
